Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-04-24
2007-04-24
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S023100, C424S184100
Reexamination Certificate
active
10394387
ABSTRACT:
Immunostimulatory polynucleotide-immunomodulatory molecule conjugate compositions are disclosed. These compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the conjugate includes at least one immunostimulatory oligonucleotide nucleotide sequence (ISS). Methods of modulating an immune response upon administration of the polynucleotide-immunomodulatory conjugate preparation to a vertebrate host are also disclosed.
REFERENCES:
patent: 1234718 (1917-07-01), Hilleman et al.
patent: 3725545 (1973-04-01), Maes
patent: 3906092 (1975-09-01), Hilleman et al.
patent: 4849513 (1989-07-01), Smith et al.
patent: 5015733 (1991-05-01), Smith et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5268365 (1993-12-01), Rudolph et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5278302 (1994-01-01), Caruthers et al.
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5780448 (1998-07-01), Davis
patent: 6037329 (2000-03-01), Baird et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6225292 (2001-05-01), Raz et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 0 468 520 (1992-01-01), None
patent: 855 184 (1997-01-01), None
patent: 1234718 (1969-09-01), None
patent: WO 96/02555 (1995-02-01), None
patent: WO 95/05853 (1995-03-01), None
patent: WO 95/26204 (1995-03-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/18810 (1997-10-01), None
patent: WO 98/37919 (1998-02-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 01/35991 (2001-05-01), None
Roman, M. et al. (1998) “Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.”Nature Medicine, vol. 3, No. 8:849-854.
Hodes, “T-Cell Mediated Regulation: Help and Suppression”, 1989, Fundamental Immunology, pp. 587-620.
McCluskie et al., “Novel Strategies Using DNA for the Induction of Mucosal Immunity”, 1999, Critical Reveiws in Immunology 19:303-329.
Krieg et al., “the Role of CpG dinucleotides in DNA vaccines”, 1998, Trends in Microbiology, vol. 6, No. 1, pp. 23-27.
Agrawal, et al.(1986). “Efficient methods for attaching non-radioactive labels to the 5′ ends of synthetic oligodeoxyribonucleotides”Nuclec Acids Res. vol. 14: 6227-6245.
Ballas, Z.K., et al., (1996). “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA”,Journal of Immunology, vol. 157: 1840-1845.
Benoit, et al. (1987). “Strategies for antibody production and radioimmunoassays”Neuromethods, vol. 6: 43-72.
Bischoff, et al. (1987). “Introduction of 5′-terminal functional groups into synthetic oligonucleotides for selective immobilization”Anal. Biochem., vol. 164: 336-344.
Blanks, et al. (1988). “An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins”Nucleic Acids Res., vol. 16: 10283-10299.
Boujrad, et al. (1993). “Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor”Proc. Natl. Acad. Sci. USA, vol. 90: 5728-31.
Branda, R.F., et al. (1996). “Amplification of antibody production by phosphorothioate oligodeoxynucleotides”The J. of Laboratory&Clinical Medicine, vol. 128(3): 329-338.
Connolly (1985). “Chemical synthesis of oligonucleotides containing a free sulphydryl group and subsequent attachment of thiol specificprobes”Nucleic Acids Res., vol. 13: 4485-4502.
Connolly (1987). “The synthesis of oligonucleotides containing a primary amino group at the 5′-terminus”Nucleic Acids Res., vol. 15: 3131-3139.
Corey, et al. (1987). “Generation of a hybrid sequence-specific single-stranded deoxyribonucleotide”Science, vol. 238 :1401-1403.
Coull, et al.(1986). “A novel method for the introduction of an aliphatic primary amino group at the 5′ terminus of synthetic oligonucleotides”Tetrahedron Lett., vol. 27: 3991-3994.
Czerkinsky, et al. (1989). “Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues”Infect. Immun., vol. 57: 1072-1077.
Dertzbaugh et al. (1993). “Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines”Infect. Immun., vol. 61: 48-55.
Geoghegan et al., (1992). “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine”Bioconjug. Chem., vol. 3: 138-146.
Goodchild (1990). “Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties”Bioconjugate Chem., vol. 1: 165.
Grabarak, et al. (1990). “Zero-length crosslinking procedure with the use of active esters”Anal Biochem., vol. 185: 131-135.
Haralambidis, et al.(1990). “The synthesis of polyamide-oligonucleotide conjugate molecules”Nucleic Acids Res., vol. 18: 493-499.
Haralambidis, et al.(1990). “The preparation of polymide-oligonucleotide probes containing multiple non-radioactive”Nucleic Acids Res., vol. 18: 501-505.
Kämper, et al. (1989). “New recombinant linear DNA-elements derived fromKluyveromyces lactiskiller plasmids”Nucleic Acids Res., vol. 17: 1781-1794.
Kessler (1992). “Nonradioactive Labeling Methods for Nucleic Acids” in L.J. Kricka (ed)Nonisotopic DNA Probe Techniques, Academic Press.
Kremsky, et al.(1987). “Immobilization of DNA via oligonucleotides containing aldehyde or carboxylic acid group at the 5′ terminus”Nucleic Acids Res., vol. 15: 2891-2902.
Krieg, et al.(1989). “A role for endogenous retroviral sequences in the regulation of lymphocyte activation”J. Immunol., vol. 1443: 2448-2451.
Krieg, et al. (1995). “CpG motifs in bacterial DNA trigger direct B-cell activation”Nature, vol. 374: 546-549.
Krieg, et al.(1996). “Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs”Antisense Nucl. Acid Drug Dev., vol. 6: 133-139.
Kreig, et al.(1996). “Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA”Trends in Microbiol., vol. 4: 73-77.
Nashar, et al.(1993). “Current progress int eh development of the B subunits of cholera toxin andEscherichia coliheat-labile enerotoxin as carriers for the oral delivery of heterologous antigens and epitopes”Vaccine, vol. 11: 235-240.
O'Shannessy, et al.(1985). “Specific conjugation reactions of the oligosaccharide moieties of immunoglobins”J. Applied Biochem., vol. 7: 347-355.
Raz et al.(1996). “Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity”Arthritis&Rhuematism, vol. 39(9): 615.
Raz et al.(1996)., “Preferential Induction of a Th1 Immune Response and Inhibition of Specific IgE Antibody Formation by Plasmid DNA Immunization”,Proceedings of the Natl Academy of Sci. USA, vol. 93: 5141-5145.
Roget, et al. (1989). “Synthesis and use of labelled nucleoside phosphoramidite building blocks bearing a reporter group: biotinyl, dinitrophenyl, pyrenyl, and dansyl”Nucl
Carson Dennis A.
Raz Eyal
Roman Mark
Borden Paula A.
Bozicevic Field & Francis LLP
Campell Bruce R.
Francis Carol L.
Horning Michelle
LandOfFree
Immunostimulatory polynucleotide/immunomodulatory molecule... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunostimulatory polynucleotide/immunomodulatory molecule..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory polynucleotide/immunomodulatory molecule... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763615